Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
Date:3/3/2010

"2009 was a tremendous year for Jazz Pharmaceuticals in continuing our mission to help improve patients' lives.  Our sales team delivered outstanding performance in 2009, educating physicians on the appropriate use of our products, which resulted in records for prescriptions of both XYREM and LUVOX CR," said Bob Myers, President of Jazz Pharmaceuticals.

Research and development expenses for the quarter ended December 31, 2009 were $6.3 million, compared to $14.7 million for the quarter ended December 31, 2008.  For the year ended December 31, 2009, research and development expenses were $36.6 million, compared to $70.0 million for the year ended December 31, 2008.  Research and development expenses in both 2009 and 2008 primarily reflect the expenses relating to Phase III clinical activities for the company's JZP-6 product candidate, sodium oxybate for the treatment of fibromyalgia.  In 2009, the company completed the second of two Phase III clinical studies and submitted a New Drug Application (NDA) for JZP-6 to the U.S. Food and Drug Administration (FDA) in December.  The NDA for JZP-6 was filed by the FDA in February 2010 and the target date for the FDA to complete its review under the Prescription Drug User Fee Act (PDUFA) is Oct
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... 2014  DigiPath, Inc. (OTCBB and OTCQB: DIGP), a ... cannabis testing and education markets, announced today that has ... not previously disclosed or, to its knowledge, any other ... "We have noticed unusual price and volume ... days," said Steve Barbee , CEO of DigiPath. ...
(Date:7/30/2014)... Coordinators, Inc. (PCI) is pleased to announce it has ... Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug development ... manufacturing, as well as Clinical Packaging, Labeling, and global ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... FDA approved Makena (hydroxyprogesterone caproate) in February 2011 ... births in women who have had at least one ... approved, a version of the active ingredient of Makena ... drug from a pharmacist who compounded the drug.  In ...
... N.J., Nov. 8, 2011 Covance Inc. (NYSE: ... Credit Suisse Healthcare Conference on Thursday, November 10, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
Cached Medicine Technology:FDA Statement on Makena 2Covance to Present at Credit Suisse 2011 Healthcare Conference 2
(Date:7/30/2014)... (HealthDay News) -- Clues to whether a person is at ... a new study suggests. Chemical changes to a gene ... spur suicidal thoughts and behaviors, the study,s authors explained. Spotting ... to a patient,s risk for suicide, they said. "Suicide ... been stymied in our prevention efforts because we have no ...
(Date:7/30/2014)... digital pathology market was valued at an estimated $250.2 million ... of 11.8%, to reach an estimated $437 million by 2018. ... expected to continue to rise in the coming years as ... pathologists to be efficient and this leads to improved quality ... was valued at $128.9 million and accounted for the largest ...
(Date:7/30/2014)... news release is available in French . ... led by Claude Gronfier (Inserm Unit 846: Stem Cell ... a study under real conditions on the body clocks ... The researchers have shown that a particular kind of ... rhythms are correctly synchronised despite the absence of sunlight. ...
(Date:7/30/2014)... with depression as preschoolers are likely to suffer from ... shows. , Depressed preschoolers were 2.5 times more likely ... school than kids who were not depressed at very ... of Medicine in St. Louis. , Their study is ... Journal of Psychiatry . , "It,s the same old ...
(Date:7/30/2014)... have found that a support program administered entirely ... symptoms in informal caregivers, such as family or ... published online in advance of print in the ... caring for people with Alzheimer,s disease or other ... deal of pressure," said principal investigator Geoffrey Tremont, ...
Breaking Medicine News(10 mins):Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Dimly lit working environments: Correcting your body clock is possible! 2Health News:Dimly lit working environments: Correcting your body clock is possible! 3Health News:Dimly lit working environments: Correcting your body clock is possible! 4Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3Health News:Study: Telephone support program beneficial for caregivers of those with dementia 2
... E-coli 0157, which is a stark eye-opener that adequate measures ... fatal food poisoning infection//. Three fresh cases, not connected to ... in South Lanarkshire, were confirmed yesterday. , ,A warning ... its dangers. But this by no means is to instigate ...
... at an IVF clinic almost destroyed their lives. In an interview ... they had to undergo when they came to know that the ... ,The couple had twins and it was quite obvious that ... by Leeds NHS Trust. "I was physically sick. The thought that ...
... says, as smoking, eating poor diets like too little fish, fruit and vegetables puts human ... ... ,Insufficient consumption of ... European Food Safety Authority, Netherland says. ,Dutch National Institute for Public Health and ...
... of exercise results from an increase in a protein ... and cause cell death. ,A study reports ... inhibits the action of another protein called insulin-like growth ... due to which the result appears. ,In ...
... people have died of heat and hundreds of people suffering ... Punjab province// , Daily Times newspaper reported Monday. ,At ... said. ,Most of the deaths were reported from ... in Multan and 48 degrees in Dera Ghazi Khan and ...
... Gurgaon (Haryana). When millions of disabled people are still dreaming ... has etched out// her own identity as a voice and ... the blind community faces a lot of barriers ranging from ... to be different can help them to overcome all of ...
Cached Medicine News:Health News:Unhealthy Diet Reduces Life Expectancy 2Health News:'Being Disabled Is Not a Barrier to Success' 2
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
Medicine Products: